Cytokines and β-Cell Biology: from Concept to Clinical Translation
Marc Y. Donath,
Joachim Størling,
Lukas A. Berchtold,
Nils Billestrup and
Thomas Mandrup-Poulsen
The Clinic for Endocrinology and Diabetes (M.Y.D.), University Hospital Zurich, CH-8091 Zurich, Switzerland; Department for Translational Diabetology (J.S., L.A.B., N.B., T.M.-P.), Steno Diabetes Center, DK-2820 Gentofte, Denmark; and Core Unit for Medical Research Methodology (T.M.-P.), Institute of Biomedicine, Faculty of Health Sciences, University of Copenhagen, DK-2200 Copenhagen N, Denmark
Correspondence: Address all correspondence and requests for reprints to: Thomas Mandrup-Poulsen, M.D., DMSc, Department for Translational Diabetology, Steno Diabetes Center, Niels Steensensvej 2, DK-2820 Gentofte, Denmark. E-mail: tmpo{at}steno.dk
The tale of cytokines and the β-cell is a long story, startingwith in vitro discovery in 1984, evolving via descriptive andphenomenological studies to detailed mapping of the signallingpathways, gene- and protein expression patterns, molecular andbiochemical effector mechanisms to in vivo studies in spontaneouslydiabetic and transgenic animal models. Only very recently havesteps been taken to translate the accumulating compelling preclinicaldata into clinical trials. The aim of this chapter is to presentan overview of early and recent key observations from our owngroups as well as other laboratories that serve to illuminatethe road from concept to clinical translation.
This article has been cited by other articles:
A. H. Xiang, M. Kawakubo, E. Trigo, S. L. Kjos, and T. A. Buchanan Declining {beta}-Cell Compensation for Insulin Resistance in Hispanic Women With Recent Gestational Diabetes Mellitus: Association with changes in weight, adiponectin, and C-reactive protein
Diabetes Care,
February 1, 2010;
33(2):
396 - 401.
[Abstract][Full Text][PDF]
G. Lacraz, F. Figeac, J. Movassat, N. Kassis, and B. Portha Diabetic GK/Par rat {beta}-cells are spontaneously protected against H2O2-triggered apoptosis. A cAMP-dependent adaptive response
Am J Physiol Endocrinol Metab,
January 1, 2010;
298(1):
E17 - E27.
[Abstract][Full Text][PDF]
V. A. Fonseca Defining and Characterizing the Progression of Type 2 Diabetes
Diabetes Care,
November 1, 2009;
32(suppl_2):
S151 - S156.
[Full Text][PDF]
S. B. Widenmaier, Z. Ao, S.-J. Kim, G. Warnock, and C. H. S. McIntosh Suppression of p38 MAPK and JNK via Akt-mediated Inhibition of Apoptosis Signal-regulating Kinase 1 Constitutes a Core Component of the {beta}-Cell Pro-survival Effects of Glucose-dependent Insulinotropic Polypeptide
J. Biol. Chem.,
October 30, 2009;
284(44):
30372 - 30382.
[Abstract][Full Text][PDF]
K. Bouzakri, P. Ribaux, and P. A. Halban Silencing Mitogen-activated Protein 4 Kinase 4 (MAP4K4) Protects Beta Cells from Tumor Necrosis Factor-{alpha}-induced Decrease of IRS-2 and Inhibition of Glucose-stimulated Insulin Secretion
J. Biol. Chem.,
October 9, 2009;
284(41):
27892 - 27898.
[Abstract][Full Text][PDF]
J. A. Ehses, G. Lacraz, M.-H. Giroix, F. Schmidlin, J. Coulaud, N. Kassis, J.-C. Irminger, M. Kergoat, B. Portha, F. Homo-Delarche, et al. IL-1 antagonism reduces hyperglycemia and tissue inflammation in the type 2 diabetic GK rat
PNAS,
August 18, 2009;
106(33):
13998 - 14003.
[Abstract][Full Text][PDF]
N. Moller, L. C. Gormsen, O. Schmitz, S. Lund, J. O. L. Jorgensen, and N. Jessen Free Fatty Acids Inhibit Growth Hormone/Signal Transducer and Activator of Transcription-5 Signaling in Human Muscle: A Potential Feedback Mechanism
J. Clin. Endocrinol. Metab.,
June 1, 2009;
94(6):
2204 - 2207.
[Abstract][Full Text][PDF]
X. Huang, D. J. Moore, R. J. Ketchum, C. S. Nunemaker, B. Kovatchev, A. L. McCall, and K. L. Brayman Resolving the Conundrum of Islet Transplantation by Linking Metabolic Dysregulation, Inflammation, and Immune Regulation
Endocr. Rev.,
August 1, 2008;
29(5):
603 - 630.
[Abstract][Full Text][PDF]
V. Poitout and R. P. Robertson Glucolipotoxicity: Fuel Excess and {beta}-Cell Dysfunction
Endocr. Rev.,
May 1, 2008;
29(3):
351 - 366.
[Abstract][Full Text][PDF]
